Months af­ter IPO, No­var­tis spin­out resTOR­bio wins on PhI­Ib da­ta — stock soars

Just six months af­ter its de­but on the Nas­daq, resTOR­bio is trot­ting out late-stage da­ta this morn­ing for its lead drug can­di­date — a TORC1 in­hibitor they’re hop­ing will pre­vent res­pi­ra­to­ry in­fec­tions in el­der­ly folks. While it flopped in a com­bo tri­al, the com­pa­ny’s drug met its pri­ma­ry end­point when test­ed by it­self.

In­vestors are thrilled with the news, with resTOR­bio’s share price $TORC fly­ing up 161% as of press time. Yes­ter­day’s close was at $9.01 per share, and to­day its so far climbed to $23.50. If it holds, that’s a de­cent jump from its IPO price of $14 to $16 per share.

Joan Man­nick

The drug — spun out of No­var­tis in­to its own start­up just last year — is now called RTB101, al­though it once went un­der the code name BEZ235. In a Phase IIb tri­al, the 10 mg dose of the drug showed a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in res­pi­ra­to­ry in­fec­tions when tak­en by pa­tients once a day. That co­hort saw a 30.6% de­crease in the per­cent­age of pa­tients who de­vel­oped a res­pi­ra­to­ry in­fec­tion when com­pared to the place­bo co­hort: p=0.026.

In­ter­est­ing­ly, the drug flopped big time when test­ed in com­bi­na­tion with an al­ready-ap­proved im­muno­sup­pres­sant called everolimus, an mTOR in­hibitor of­ten used to pre­vent the re­jec­tion of or­gan trans­plants. When resTOR­bio test­ed RTB101 com­bi­na­tion with everolimus, they found no de­crease in the per­cent­age of pa­tients with res­pi­ra­to­ry in­fec­tions. The drug al­so saw lousy re­sults when the 10 mg dose was tak­en twice dai­ly in­stead of once.

“We’re find­ing that less TORC1 in­hi­bi­tion works bet­ter than more TORC1 in­hi­bi­tion,” the com­pa­ny’s co-founder and CMO Joan Man­nick tells me. They saw a sim­i­lar re­sponse in their Phase IIa tri­al, she said.

Chen Schor

The com­pa­ny’s CEO Chen Schor said he wasn’t too con­cerned that the com­bo and dou­ble dos­es didn’t per­form well. In fact, the drug work­ing as a monother­a­py is ben­e­fi­cial.

“We pre­fer to move for­ward with the monother­a­py, be­cause it’s eas­i­er to man­u­fac­ture,” he said. “That was our hope.”

The com­pa­ny al­so homed in on a few spe­cif­ic pa­tient groups in which they saw more promis­ing re­sults. For ex­am­ple, in asth­ma pa­tients, they saw a 68% re­duc­tion in res­pi­ra­to­ry in­fec­tions (p=0.0002), and in pa­tients 85 years or old­er they saw 67% (p=0.007). The tri­al in­volved some 650 pa­tients, ac­cord­ing to clin­i­cal­tri­als.gov, but when resTOR­bio whit­tles down the pa­tient group to these se­lect pop­u­la­tions, we’re talk­ing much few­er peo­ple. I asked Man­nick just how many we’re talk­ing here. In asth­ma, it was on­ly 47 pa­tients, she said, and a mere 27 peo­ple were 85 years old and old­er.

But Man­nick de­fend­ed the da­ta’s sig­nif­i­cance re­gard­less of the small­er pa­tient group. “When you have few­er pa­tients, it’s much hard­er to reach sta­tis­ti­cal sig­nif­i­cance,” she said. “You have to have a big ef­fect.”

The com­pa­ny is meet­ing with the FDA at the end of this year to dis­cuss how it should move for­ward with a Phase III tri­al. Man­nick and Schor said the com­pa­ny will be shoot­ing for a sim­i­lar tri­al de­sign, in which they test co­horts of nar­row pa­tient groups with­in the same tri­al.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe.

The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). They have mapped out €1 billion in expected sales by 2022 and 3,100 employees for the new operations headquartered in France.

UP­DAT­ED: NGM Bio takes leap for­ward in crowd­ed NASH field

South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibrotic activity, NASH resolution and liver fat reduction, sending the company’s stock soaring.

There are an estimated 50+ companies focused on developing drugs for non-alcoholic steatohepatitis, or NASH, a common liver disease that has long flummoxed researchers. The first wave of NASH drug developers struggled with efficacy as well as safety — and companies big and small have crashed and burned.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Mickey Kertesz, KidsandArtOrg via YouTube

Soft­Bank's newest, $165M biotech in­vest­ment looks for in­fec­tious traces in the blood

SoftBank has found its newest biotech investment.

The Japanese bank has invested $165 million into Karius, a company that uses blood tests to diagnose infectious diseases, as part of its new Vision Fund 2. The full scope of the new fund has yet to be announced, but the first and newly-beleaguered Vision Fund poured $100 billion into technology companies, including the biotechs Vir Biotechnology and Roivant and the sequencing company 10x Genomics.

Methicillin-resistant Staph aureus (Shutterstock)

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

An experimental drug that promises to be the first anti-infective agent to prove superior to vancomycin — an antibiotic approved in 1958 — has notched the FDA’s “breakthrough” status.

ContraFect said the designation was based on Phase II data in which exebacase was tested against a superbug known as methicillin-resistant Staph aureus, or MRSA. In a subgroup analysis, the clinical responder rate at day 14 was 42.8% higher than that among those treated with standard of care, the company said (p=0.010).

Zhong Nanshan, CGTN via YouTube

Har­vard joins coro­n­avirus fight with $115 mil­lion and a high-pro­file Chi­nese part­ner

For two months, as the novel coronavirus swelled from a few early cases tied to a Wuhan market to a global epidemic, most of the world’s focus and dollars have flowed toward emergency initiatives: building vaccines at a record pace, plucking experimental antivirals out of freezers to see what sticks and immunizing mice for new antibodies.

Now a new and well-funded collaboration between Harvard and a top Chinese research institute will play the long game. In a 5-year, $115 million initiative backed by China Evergrande Group, researchers from the Harvard Medical School, Harvard T.H. Chan School of Public Health and Guangzhou Institute for Respiratory Health will study the virus in an effort to develop therapies against infections by the novel coronavirus, known as SARS–CoV-2, and to prevent new ones.

No­var­tis gets a boost in block­buster mul­ti­ple scle­ro­sis race with Roche

In the first step of what’s likely to be a long and uphill battle for the drugmaker, the FDA has accepted Novartis’s BLA submission for a new multiple sclerosis drug and given it priority review. The PDUFA date for the potential blockbuster drug is in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Juergen Horn

An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 million in 2017 to acquire Nexvet Biopharma and its pipeline of monoclonal antibodies. Juergen Horn, Nexvet’s former chief product development officer, has now secured $15 million for his own biologic company for animals: Invetx.

Buoyed by emerging advances in gene therapies for humans, scientists have started looking at harnessing the technology for animals setting up companies such as Penn-partnered Scout Bio and George Church-founded Rejuvenate Bio. But akin to Nexvet, Invetx is working on leveraging the time-tested science of monoclonal antibodies to treat chronic diseases that afflict man’s best friend.

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

As the coronavirus originating out of Wuhan spreads to South Korea, Italy and Iran, stoking already intense fears of a pandemic, GlaxoSmithKline has found another pair of trusted hands to place its adjuvant system. China’s Clover Biopharmaceuticals will add the adjuvant to its preclinical, protein-based vaccine candidate against SARS-CoV-2.

Clover, which is based in the inland city of Chengdu, boasts of a platform dubbed Trimer-Tag that produces covalently-trimerized fusion proteins. Its candidate, COVID-19 S-Trimer, resembles the viral spike (S)-protein found in the virus.